Combined acetylcholinesterase inhibitor and quaternary ammonium antimuscarinic therapy to alter progression of cognitive diseases
AssigneeQaam Pharmaceuticals, LLC
InventorSteven A. Rich
Life of this patent
Estimating the term…
Abstract
A method administers quaternary ammonium anti-cholinergic muscarinic receptor antagonists in combination with acetyl-cholinesterase inhibitors to treat either cognitive impairment or acute delirium. This therapy results in a modification of a cognitive disorder or disease, namely a slow down in the disease progression. In one preferred embodiment, the disease is dementia with Lewy Bodies. New formulations for quaternary ammonium anti-cholinergic muscarinic receptor antagonists are also disclosed.
Claims40
1-23. (canceled)
In human patients suffering from a cognitive disorder selected from the group consisting of cognitive impairment and acute dementia a method for improving cognitive function comprising administering to the patient a therapeutic amount of the combination of rivastigmine and glycopyrrolate.
A method for treating a cognitive disorder comprising administering to a patient a therapeutic amount of glycopyrrolate and a therapeutic amount of rivastigmine.
A method for treating Dementia with Lewy Bodies comprising administering to a patient a therapeutic amount of glycopyrrolate and from about 1.5 to about 24 mg/day orally, or about 4.6 to about 17.4 mg/day by transdermal patch of rivastigmine.
In human patients suffering from a cognitive disorder, a method for improving cognitive function comprising administering to the patient a therapeutic amount of the combination of an acetylcholinesterase inhibitor and an anti-cholinergic muscarinic receptor antagonist.
A method for treating a cognitive disorder comprising administering to a patient a therapeutic amount of an acetylcholinesterase inhibitor and an anti-cholinergic muscarinic receptor antagonist.
A method to inhibit undesired side effects of acetyl cholinesterase inhibitors used to treat a patient suffering from a cognitive disorder selected from the group consisting of acute delirium and cognitive impairment comprising administering to the patient a therapeutic amount of solefenacin.
In human patients suffering from a cognitive disorder selected from the group consisting of cognitive impairment and acute dementia a method for improving cognitive function comprising administering to the patient a therapeutic amount of the combination of donepezil and glycopyrrolate.
A method for treating a cognitive disorder comprising administering to a patient a therapeutic amount of glycopyrrolate and a therapeutic amount of donepezil.
A method to inhibit undesired side effects of donepezil used to treat a patient suffering from a cognitive disorder selected from the group consisting of acute delirium and cognitive impairment comprising administering a therapeutic amount of glycopyrrolate.
Dependencies are inferred from the claim text.